Introduction: Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive memory loss and mental deterioration. AD is the most common form of presenile dementia and is estimated to affect over 4.7 million Americans. Due to rising health care costs and the age of onset of those affected, AD has become a serious problem nationwide. In 2013 the Center for Disease Control (CDC) estimated that approximately $203 billion was spent on AD-related healthcare. The CDC also estimates that the number of affected individuals nationwide will quadruple by 2050 and further estimates a national expenditure of US$1.1 trillion (PMID 23507120). The cause of AD remains unidentified despite the best efforts of doctors and researchers to identify its cause or a treatment method. The CDC has identified AD as the sixth leading cause of death in the United States, after cancer, heart disease, lung disease, and accidents (PMID 23507120). However, unlike AD, science has made incremental progress toward the care and treatment of individuals suffering from the other five major causes. Soon, the nation is expected to witness the rise of AD among the country's leading causes of death. There is currently no known cure for AD or a way to slow its progression. An affected individual lives on average 8 years from the onset of the first symptoms (PMID: 19836639). The mechanisms involved in the pathology of AD are still largely unknown. However, science knows that amyloid beta (Aβ) peptide is involved in at least some of the pathologies seen in disease progression. Evidence for the involvement of Aβ in AD is expressed through the widespread accumulation of Aβ peptide throughout the ... half of the article ...... the cause leading to AD is imminent. By analyzing all the various pathologies caused by the Aβ peptide in unison, he suggests that it may not be correct to consider AD as an individual disease, but as a spectrum disorder, causing the overall deficits so commonly observed in AD victims. Furthermore, the development of CAA occurs in 90% of patients with AD (PMID: 3551211). This comorbidity between AD and CAA or any other amyloid-related pathology suggests that the interaction between the developing diseases plays an important role in the prognosis of AD. The importance of identifying dysfunctions associated with mutations in the APP gene is crucial for understanding AD. In doing so, it offers the scientist the ability to discern whether a dysfunction found in AD pathology is a result caused by the disease itself or whether it may be a potential cause of AD.